China · Delayed Price · Currency is CNY GemPharmatech Statistics
Total Valuation
GemPharmatech has a market cap or net worth of CNY 7.82 billion. The enterprise value is 7.00 billion.
| Market Cap | 7.82B |
| Enterprise Value | 7.00B |
Important Dates
The next estimated earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | Jun 9, 2026 |
Share Statistics
GemPharmatech has 408.97 million shares outstanding. The number of shares has decreased by -2.43% in one year.
| Current Share Class | 408.97M |
| Shares Outstanding | 408.97M |
| Shares Change (YoY) | -2.43% |
| Shares Change (QoQ) | -4.03% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 17.63% |
| Float | 165.23M |
Valuation Ratios
The trailing PE ratio is 47.73 and the forward PE ratio is 41.59.
| PE Ratio | 47.73 |
| Forward PE | 41.59 |
| PS Ratio | 9.42 |
| PB Ratio | 3.43 |
| P/TBV Ratio | 3.55 |
| P/FCF Ratio | 48.48 |
| P/OCF Ratio | 31.34 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.17, with an EV/FCF ratio of 43.36.
| EV / Earnings | 43.80 |
| EV / Sales | 8.42 |
| EV / EBITDA | 27.17 |
| EV / EBIT | 40.89 |
| EV / FCF | 43.36 |
Financial Position
The company has a current ratio of 3.58, with a Debt / Equity ratio of 0.11.
| Current Ratio | 3.58 |
| Quick Ratio | 3.17 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 1.01 |
| Debt / FCF | 1.61 |
| Interest Coverage | 25.59 |
Financial Efficiency
Return on equity (ROE) is 7.20% and return on invested capital (ROIC) is 10.77%.
| Return on Equity (ROE) | 7.20% |
| Return on Assets (ROA) | 3.88% |
| Return on Invested Capital (ROIC) | 10.77% |
| Return on Capital Employed (ROCE) | 7.16% |
| Weighted Average Cost of Capital (WACC) | 9.03% |
| Revenue Per Employee | 522,396 |
| Profits Per Employee | 100,478 |
| Employee Count | 1,590 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 4.14 |
Taxes
In the past 12 months, GemPharmatech has paid 28.04 million in taxes.
| Income Tax | 28.04M |
| Effective Tax Rate | 14.93% |
Stock Price Statistics
The stock price has increased by +51.95% in the last 52 weeks. The beta is 0.91, so GemPharmatech's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +51.95% |
| 50-Day Moving Average | 19.32 |
| 200-Day Moving Average | 17.52 |
| Relative Strength Index (RSI) | 54.10 |
| Average Volume (20 Days) | 4,042,287 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GemPharmatech had revenue of CNY 830.61 million and earned 159.76 million in profits. Earnings per share was 0.40.
| Revenue | 830.61M |
| Gross Profit | 530.03M |
| Operating Income | 171.12M |
| Pretax Income | 187.80M |
| Net Income | 159.76M |
| EBITDA | 244.42M |
| EBIT | 171.12M |
| Earnings Per Share (EPS) | 0.40 |
Balance Sheet
The company has 1.09 billion in cash and 259.51 million in debt, with a net cash position of 826.11 million or 2.02 per share.
| Cash & Cash Equivalents | 1.09B |
| Total Debt | 259.51M |
| Net Cash | 826.11M |
| Net Cash Per Share | 2.02 |
| Equity (Book Value) | 2.28B |
| Book Value Per Share | 5.81 |
| Working Capital | 1.23B |
Cash Flow
In the last 12 months, operating cash flow was 249.66 million and capital expenditures -88.28 million, giving a free cash flow of 161.38 million.
| Operating Cash Flow | 249.66M |
| Capital Expenditures | -88.28M |
| Depreciation & Amortization | 73.30M |
| Net Borrowing | 6.17M |
| Free Cash Flow | 161.38M |
| FCF Per Share | 0.39 |
Margins
Gross margin is 63.81%, with operating and profit margins of 20.60% and 19.23%.
| Gross Margin | 63.81% |
| Operating Margin | 20.60% |
| Pretax Margin | 22.61% |
| Profit Margin | 19.23% |
| EBITDA Margin | 29.43% |
| EBIT Margin | 20.60% |
| FCF Margin | 19.43% |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 1.15%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 1.15% |
| Dividend Growth (YoY) | 57.14% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 38.16% |
| Buyback Yield | 2.43% |
| Shareholder Yield | 3.58% |
| Earnings Yield | 2.04% |
| FCF Yield | 2.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GemPharmatech has an Altman Z-Score of 7.8 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.8 |
| Piotroski F-Score | 6 |